annb0t
Top 20
-- If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B
-- This milestone underscores CSL Behring's promise to develop and deliver a truly unique portfolio of patient-focused therapies for people with rare and serious medical conditions
KING OF PRUSSIA, Pa., May 24, 2022 /PRNewswire/ -- Global biotherapeutics leader CSL Behring, a business of CSL, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biolo...
>>> Read more: FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review
-- This milestone underscores CSL Behring's promise to develop and deliver a truly unique portfolio of patient-focused therapies for people with rare and serious medical conditions
KING OF PRUSSIA, Pa., May 24, 2022 /PRNewswire/ -- Global biotherapeutics leader CSL Behring, a business of CSL, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biolo...
>>> Read more: FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review
